You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥股普遍跑輸大市 科濟、康希諾及騰盛博藥挫6%-8%
恆指及國指現報19,172及6,545,跌近0.3%及0.5%,總成交額僅579億元。 內地昨天新增1,499宗本土新冠病例,包括264宗本土確診及1,235宗本土無症狀感染個案。然而,醫藥板塊今天普遍跑輸大市,下月起正式委任朱青為中國研發主管的騰盛博藥-B(02137.HK)四連跌,繼昨天挫近7%,今天股價進一步跌破5月初所創上市低位7.15元,最低見6.57元,現報6.66元,續挫8.1%,成交增至875萬股。 康希諾(06185.HK)旗下吸入用重組新冠疫苗被國家藥監局同意作為加強針於內地納入緊急使用,該股繼昨天急彈至57.25元(受制20天線)收市僅回升7%後,今天股價回吐6.2%報50.2元;康希諾A(688185.SH)也回吐4.8%報134.75元人民幣。 科濟藥業-B(02171.HK)七連跌,最低見14.9元,現報15.32元,續跌6%。信達生物(01801.HK)反覆四連跌兼失守百天線(29.7元),現報28.75元,續跌3.8%。金斯瑞生物(01548.HK)跌2.7%報23.15元。此外,京東健康(06618.HK)和藍籌阿里健康(00241.HK)反覆續跌3.5%及4%,報51.1元及4.25元。 然而,藥明康德(02359.HK)扭三連跌,股價由逾兩年低位反覆回升1%,報82元;藍籌藥明生物(02269.HK)六連跌後,今天股價反覆微彈0.4%報64.25元。復星醫藥(02196.HK)也扭轉昨天急挫頹勢,股價由約兩年半低位回升0.7%報22元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account